Silence Therapeutics PLC Additional Listing (4336G)

TIDMSLN

RNS Number : 4336G

Silence Therapeutics PLC

23 July 2019

Additional listing

July 23, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 60,000 new ordinary shares of 5p each ("New Ordinary Shares") following the exercise of share options under the Employee Share Option Scheme.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 29 July 2019. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 77,545,652. The Company holds no shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 Silence Therapeutics plc                          Tel: +44 (0)20 3457 
  Dr David Horn Solomon, Chief Executive Officer    6900 
 Peel Hunt LLP (Nominated Adviser and Broker)      Tel: +44 (0)20 7418 
  James Steel/Oliver Jackson                        8900 
 European IR                                       Tel: +44 (0) 20 
  Consilium Strategic Communications                3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  silencetherapeutics@consilium-comms.com 
 US IR                                              Tel: +1 (443) 213-0505 
  Westwicke Partners 
  Peter Vozzo 
  peter.vozzo@westwicke.com

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ALSPGUAPMUPBGUW

(END) Dow Jones Newswires

July 23, 2019 06:27 ET (10:27 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Oct 2024 to Nov 2024